NLRP3 and myasthenia gravis: The selective NLRP3 inhibitor 1,2,4‐TTB can inhibit ASC oligomerization and the interaction between NLRP3 and ASC, reducing caspase‐1 activation and IL‐1β secretion in immortalized mouse bone marrow‐derived macrophages (iBMDM) and primary murine MG, significantly improving EAE progression and demyelination [130].